Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
49
ATAI Quote, Financials, Valuation and Earnings
Last price:
$4.20
Seasonality move
:
-13.19%
Day range:
$4.11 - $4.36
52-week range:
$1.15 - $6.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
257.46x
P/B ratio:
9.55x
Volume:
6.7M
Avg. volume:
3.7M
1-year change:
240.65%
Market cap:
$1.5B
Revenue:
$308K
EPS (TTM):
-$0.74
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ATAI
Atai Beckley NV
|
$50K | -$0.12 | -82.32% | -21.86% | $12.40 |
|
ARGX
argenx SE
|
$1.1B | $4.11 | 87.13% | 205.62% | $1,010.28 |
|
MRUS
Merus NV
|
$8.7M | -$1.36 | -7.07% | -135.86% | $97.00 |
|
PHAR
Pharming Group NV
|
$91.2M | $0.00 | 11.23% | -90.74% | $31.00 |
|
PRQR
ProQR Therapeutics NV
|
$7M | -$0.17 | 32.53% | -55.96% | $8.88 |
|
QURE
uniQure NV
|
$5.2M | -$0.86 | 8.51% | -38.17% | $55.30 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ATAI
Atai Beckley NV
|
$4.20 | $12.40 | $1.5B | -- | $0.00 | 0% | 257.46x |
|
ARGX
argenx SE
|
$848.48 | $1,010.28 | $52.2B | 43.13x | $0.00 | 0% | 18.10x |
|
MRUS
Merus NV
|
$96.91 | $97.00 | $7.4B | -- | $0.00 | 0% | 121.82x |
|
PHAR
Pharming Group NV
|
$18.09 | $31.00 | $1.2B | 1,265.04x | $0.00 | 0% | 3.41x |
|
PRQR
ProQR Therapeutics NV
|
$2.17 | $8.88 | $228.6M | -- | $0.00 | 0% | 13.13x |
|
QURE
uniQure NV
|
$25.19 | $55.30 | $1.6B | -- | $0.00 | 0% | 86.07x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ATAI
Atai Beckley NV
|
1.82% | 5.268 | 0.23% | 6.93x |
|
ARGX
argenx SE
|
-- | 0.059 | -- | 4.92x |
|
MRUS
Merus NV
|
1.57% | 2.127 | 0.17% | 7.55x |
|
PHAR
Pharming Group NV
|
33.1% | -0.371 | 13.18% | 2.39x |
|
PRQR
ProQR Therapeutics NV
|
20.36% | 3.523 | 7.64% | 3.23x |
|
QURE
uniQure NV
|
69.92% | 0.547 | 14.65% | 6.94x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ATAI
Atai Beckley NV
|
$516K | -$28.4M | -82.97% | -91.85% | -3796.53% | -$25M |
|
ARGX
argenx SE
|
$837.2M | $203.8M | 24.23% | 28.06% | 30.38% | $312.8M |
|
MRUS
Merus NV
|
$11.5M | -$96.5M | -52.67% | -53.47% | -794.06% | -$90.4M |
|
PHAR
Pharming Group NV
|
$89.8M | $15.8M | 0.25% | 0.39% | 16.34% | $29.9M |
|
PRQR
ProQR Therapeutics NV
|
$2.6M | -$13.2M | -54.22% | -67.34% | -392.68% | -$15.4M |
|
QURE
uniQure NV
|
-$329K | -$50.7M | -40.98% | -382.35% | -1370.5% | -$17.7M |
Atai Beckley NV vs. Competitors
-
Which has Higher Returns ATAI or ARGX?
argenx SE has a net margin of -8157.28% compared to Atai Beckley NV's net margin of 25.88%. Atai Beckley NV's return on equity of -91.85% beat argenx SE's return on equity of 28.06%.
Company Gross Margin Earnings Per Share Invested Capital ATAIAtai Beckley NV68.89% -$0.28 $162.9M ARGXargenx SE88.32% $3.74 $6.1B -
What do Analysts Say About ATAI or ARGX?
Atai Beckley NV has a consensus price target of $12.40, signalling upside risk potential of 186.37%. On the other hand argenx SE has an analysts' consensus of $1,010.28 which suggests that it could grow by 19.38%. Given that Atai Beckley NV has higher upside potential than argenx SE, analysts believe Atai Beckley NV is more attractive than argenx SE.
Company Buy Ratings Hold Ratings Sell Ratings ATAIAtai Beckley NV10 0 0 ARGXargenx SE15 2 0 -
Is ATAI or ARGX More Risky?
Atai Beckley NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison argenx SE has a beta of 0.366, suggesting its less volatile than the S&P 500 by 63.397%.
-
Which is a Better Dividend Stock ATAI or ARGX?
Atai Beckley NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. argenx SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atai Beckley NV pays -- of its earnings as a dividend. argenx SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATAI or ARGX?
Atai Beckley NV quarterly revenues are $749K, which are smaller than argenx SE quarterly revenues of $948M. Atai Beckley NV's net income of -$61.1M is lower than argenx SE's net income of $245.4M. Notably, Atai Beckley NV's price-to-earnings ratio is -- while argenx SE's PE ratio is 43.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atai Beckley NV is 257.46x versus 18.10x for argenx SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIAtai Beckley NV257.46x -- $749K -$61.1M ARGXargenx SE18.10x 43.13x $948M $245.4M
-
Which has Higher Returns ATAI or MRUS?
Merus NV has a net margin of -8157.28% compared to Atai Beckley NV's net margin of -786.17%. Atai Beckley NV's return on equity of -91.85% beat Merus NV's return on equity of -53.47%.
Company Gross Margin Earnings Per Share Invested Capital ATAIAtai Beckley NV68.89% -$0.28 $162.9M MRUSMerus NV94.71% -$1.26 $787.2M -
What do Analysts Say About ATAI or MRUS?
Atai Beckley NV has a consensus price target of $12.40, signalling upside risk potential of 186.37%. On the other hand Merus NV has an analysts' consensus of $97.00 which suggests that it could grow by 0.09%. Given that Atai Beckley NV has higher upside potential than Merus NV, analysts believe Atai Beckley NV is more attractive than Merus NV.
Company Buy Ratings Hold Ratings Sell Ratings ATAIAtai Beckley NV10 0 0 MRUSMerus NV2 13 0 -
Is ATAI or MRUS More Risky?
Atai Beckley NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merus NV has a beta of 1.061, suggesting its more volatile than the S&P 500 by 6.069%.
-
Which is a Better Dividend Stock ATAI or MRUS?
Atai Beckley NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merus NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atai Beckley NV pays -- of its earnings as a dividend. Merus NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATAI or MRUS?
Atai Beckley NV quarterly revenues are $749K, which are smaller than Merus NV quarterly revenues of $12.2M. Atai Beckley NV's net income of -$61.1M is higher than Merus NV's net income of -$95.5M. Notably, Atai Beckley NV's price-to-earnings ratio is -- while Merus NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atai Beckley NV is 257.46x versus 121.82x for Merus NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIAtai Beckley NV257.46x -- $749K -$61.1M MRUSMerus NV121.82x -- $12.2M -$95.5M
-
Which has Higher Returns ATAI or PHAR?
Pharming Group NV has a net margin of -8157.28% compared to Atai Beckley NV's net margin of 7.71%. Atai Beckley NV's return on equity of -91.85% beat Pharming Group NV's return on equity of 0.39%.
Company Gross Margin Earnings Per Share Invested Capital ATAIAtai Beckley NV68.89% -$0.28 $162.9M PHARPharming Group NV92.7% $0.11 $395.6M -
What do Analysts Say About ATAI or PHAR?
Atai Beckley NV has a consensus price target of $12.40, signalling upside risk potential of 186.37%. On the other hand Pharming Group NV has an analysts' consensus of $31.00 which suggests that it could grow by 71.37%. Given that Atai Beckley NV has higher upside potential than Pharming Group NV, analysts believe Atai Beckley NV is more attractive than Pharming Group NV.
Company Buy Ratings Hold Ratings Sell Ratings ATAIAtai Beckley NV10 0 0 PHARPharming Group NV2 0 0 -
Is ATAI or PHAR More Risky?
Atai Beckley NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pharming Group NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ATAI or PHAR?
Atai Beckley NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharming Group NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atai Beckley NV pays -- of its earnings as a dividend. Pharming Group NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATAI or PHAR?
Atai Beckley NV quarterly revenues are $749K, which are smaller than Pharming Group NV quarterly revenues of $96.9M. Atai Beckley NV's net income of -$61.1M is lower than Pharming Group NV's net income of $7.5M. Notably, Atai Beckley NV's price-to-earnings ratio is -- while Pharming Group NV's PE ratio is 1,265.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atai Beckley NV is 257.46x versus 3.41x for Pharming Group NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIAtai Beckley NV257.46x -- $749K -$61.1M PHARPharming Group NV3.41x 1,265.04x $96.9M $7.5M
-
Which has Higher Returns ATAI or PRQR?
ProQR Therapeutics NV has a net margin of -8157.28% compared to Atai Beckley NV's net margin of -381.88%. Atai Beckley NV's return on equity of -91.85% beat ProQR Therapeutics NV's return on equity of -67.34%.
Company Gross Margin Earnings Per Share Invested Capital ATAIAtai Beckley NV68.89% -$0.28 $162.9M PRQRProQR Therapeutics NV76.72% -$0.12 $84.2M -
What do Analysts Say About ATAI or PRQR?
Atai Beckley NV has a consensus price target of $12.40, signalling upside risk potential of 186.37%. On the other hand ProQR Therapeutics NV has an analysts' consensus of $8.88 which suggests that it could grow by 308.99%. Given that ProQR Therapeutics NV has higher upside potential than Atai Beckley NV, analysts believe ProQR Therapeutics NV is more attractive than Atai Beckley NV.
Company Buy Ratings Hold Ratings Sell Ratings ATAIAtai Beckley NV10 0 0 PRQRProQR Therapeutics NV7 0 0 -
Is ATAI or PRQR More Risky?
Atai Beckley NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.176, suggesting its less volatile than the S&P 500 by 82.397%.
-
Which is a Better Dividend Stock ATAI or PRQR?
Atai Beckley NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atai Beckley NV pays -- of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATAI or PRQR?
Atai Beckley NV quarterly revenues are $749K, which are smaller than ProQR Therapeutics NV quarterly revenues of $3.4M. Atai Beckley NV's net income of -$61.1M is lower than ProQR Therapeutics NV's net income of -$12.9M. Notably, Atai Beckley NV's price-to-earnings ratio is -- while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atai Beckley NV is 257.46x versus 13.13x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIAtai Beckley NV257.46x -- $749K -$61.1M PRQRProQR Therapeutics NV13.13x -- $3.4M -$12.9M
-
Which has Higher Returns ATAI or QURE?
uniQure NV has a net margin of -8157.28% compared to Atai Beckley NV's net margin of -2175.87%. Atai Beckley NV's return on equity of -91.85% beat uniQure NV's return on equity of -382.35%.
Company Gross Margin Earnings Per Share Invested Capital ATAIAtai Beckley NV68.89% -$0.28 $162.9M QUREuniQure NV-8.89% -$1.38 $760.4M -
What do Analysts Say About ATAI or QURE?
Atai Beckley NV has a consensus price target of $12.40, signalling upside risk potential of 186.37%. On the other hand uniQure NV has an analysts' consensus of $55.30 which suggests that it could grow by 119.54%. Given that Atai Beckley NV has higher upside potential than uniQure NV, analysts believe Atai Beckley NV is more attractive than uniQure NV.
Company Buy Ratings Hold Ratings Sell Ratings ATAIAtai Beckley NV10 0 0 QUREuniQure NV9 2 0 -
Is ATAI or QURE More Risky?
Atai Beckley NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.586, suggesting its less volatile than the S&P 500 by 41.431%.
-
Which is a Better Dividend Stock ATAI or QURE?
Atai Beckley NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atai Beckley NV pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATAI or QURE?
Atai Beckley NV quarterly revenues are $749K, which are smaller than uniQure NV quarterly revenues of $3.7M. Atai Beckley NV's net income of -$61.1M is higher than uniQure NV's net income of -$80.5M. Notably, Atai Beckley NV's price-to-earnings ratio is -- while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atai Beckley NV is 257.46x versus 86.07x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIAtai Beckley NV257.46x -- $749K -$61.1M QUREuniQure NV86.07x -- $3.7M -$80.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
